NSE filing, NSE: ORCHPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Orchid Pharma Ltd: key numbers
- Share price
- ₹839.75
- Market cap
- ₹5,029 Cr
- Revenue (annual)
- ₹811.3 Cr
- Net profit (annual)
- ₹20.55 Cr
- P/E (TTM)
- 580.2×Sector 48.7×
- Promoter holding
- 74.45%+4.61% QoQ
- FII holding
- 0.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Orchid Pharma Ltd
All →Orchid Pharma Partnership
Orchid Pharma entered a licensing and supply agreement with Laboratorio Libra for Exblifep across nine Latin American markets. The partnership is expected to represent a potential opportunity of about USD 80 million over 10 years.
Orchid Pharma Fund Raise of ₹600 Cr
Orchid Pharma's board approved an enabling resolution to raise funds of up to ₹600 Crore through equity or debt securities via various permissible modes.
- Value
- ₹600.0 Cr
Orchid Pharma Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Orchid Pharma Board Meeting Date
Orchid Pharma has scheduled a board meeting for October 20, 2026, to consider options for raising funds. The company will explore various suitable funding avenues.
Orchid Pharma Other Announcement
Orchid Pharma Ltd has filed its quarterly Shareholding Pattern, providing a routine update on promoter and public shareholding as mandated by SEBI regulations.
Orchid Pharma Annual General Meeting
Orchid Pharma held its 33rd Annual General Meeting on September 29, 2026, where shareholders considered and approved routine business resolutions and related party transactions.
Other legal & regulatory announcements
All →Banaras Beads Legal & Regulatory
Banaras Beads received an MSMED Act claim of ₹26.24 lakh from supplier Together Tech. The company disputes the claim citing supplier's breach of purchase terms.
- Value
- ₹0.26 Cr
Axis Bank Legal & Regulatory
Axis Bank disclosed a SEBI censure order against subsidiary Axis Capital Limited. No investor harm or fraudulent design was involved.
Rajshree Sugars & Chemicals Legal & Regulatory
Rajshree Sugars discloses a favorable order dropping ₹62.84 Cr Central Excise proceedings on molasses. The Commissioner ruled in the company's favor with nil financial impact.
- Value
- ₹62.84 Cr
Waaree Energies Legal & Regulatory
Waaree Energies disclosed GPCB's January 2026 closure direction for its Degam solar cell plant, since revoked and extended. Interim compensation and bank guarantees total ₹0.17 Crore.
- Value
- ₹0.17 Cr
5Paisa Capital Legal & Regulatory
5paisa Capital Ltd received a favourable income tax order for AY 2023-24, granting relief of ₹40.03 crore against a total disputed amount of ₹42.90 crore.
- Value
- ₹40.03 Cr
5Paisa Capital Legal & Regulatory
5paisa Capital's appeal against an Income Tax order for A.Y. 2023-24 was partly allowed, granting the company relief of ₹40.03 Crore.
- Value
- ₹42.90 Cr